Overview

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This is a 12-Week clinical trial in patients with Primary hypercholesterolemia or mixed dyslipidemia to study the effects of ER niacin/laropiprant on lipids.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Atorvastatin
Atorvastatin Calcium
Calcium
Niacin
Niacinamide
Nicotinic Acids
Simvastatin